RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

source https://medicalxpress.com/news/2022-09-ret-inhibitor-selpercatinib-durable-responses.html